Future FDA Approvals Will Expand Rare Disease Treatments
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 10 Analysts
Published
03 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$20.60
61.4% undervalued intrinsic discount15 Aug
US$7.96
1Y
101.0%7D
-12.2%